Three West Coast Biotechs Standardize on BioClinica
Multi-Million Dollar, Multi-Year eClinical Deals Signed in 2014
NEWTOWN, Pa., Jan. 22, 2015 /PRNewswire/ -- BioClinica®, Inc., a leading provider of outsourced clinical trial services and eClinical technologies, reported today that three mid-sized West Coast biotech organizations standardized on its eClinical Suite in 2014. These biotech companies completed 42 rapid study starts last year using a combination of Trident IRT and Express EDC technology in conjunction with BioClinica data management services. The number of studies launched is expected to climb substantially in coming months.
These and other life sciences companies have standardized on BioClinica's eClinical Solutions for the efficiencies surrounding data management and the value of highly connected data. "Using multiple BioClinica products provides advantages in data mapping and reporting," said John Hubbard, CEO and President for BioClinica. "Combining EDC and IRT, for instance, provides line-of-sight reporting across multiple studies and across programs."
Accelerated study start up times have been achieved with the aid of electronic Case Report Form (eCRF) libraries created by BioClinica. These libraries allow reuse of study forms and validated edit checks, condensing User Acceptance Testing (UAT) while creating uniformity and consistency in study builds, data extracts, and reports. Such benefits are especially attractive to growing research organizations with developing programs where new personnel must get up-to-speed quickly.
BioClinica offers mid-sized and start up biotech companies a unique value proposition. "From unlimited imports and on-demand exports to linked query and data listings to seamless integrations, our technology solutions take the customer from Phase I through pivotal trials and beyond while providing the most sponsor friendly business model in the industry," Hubbard said. It also supports growth in a more controlled way as an organization is able to focus hiring in clinical operations to manage sites and oversee monitoring activities while leaving data management to BioClinica.
The key advantage to our unique sponsor-friendly business model is our predictable pricing and unmatched support. "BioClinica customers only pay for the software they need and when they need it," Stephen Boccardo, BioClinica SVP of eClinical Business Development said. "With our extensive in-house clinical trial expertise BioClinica is viewed as an extension of our sponsors' teams rather than a vendor to be managed and monitored."
All three agreements under the multi-million dollar, multi-year deals include IRT, EDC, and data management. In addition, all three biotech organizations are evaluating OnPoint CTMS for enterprise-wide implementation and two are considering the Optimizer clinical trial supply management tool and the Compass intelligent monitoring technology.
To request a meeting with BioClinica to learn more about our eClinical Solutions or to schedule a product demonstration, call our hotline at 1-888-392-7456, email [email protected] or complete the online Contact Us form. Follow BioClinica on the Trial Blazers blog at http://www.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica.
About BioClinica, Inc.
BioClinica is a specialty clinical trials services provider that improves the development of new medical therapies by delivering expertise and technologies that enhance clinical research data and analytics, worldwide. The company offers industry-leading medical imaging services, enterprise eClinical technologies, clinical research centers and cardiovascular safety solutions that bring quality and efficiency to every phase of clinical development. BioClinica's experience spans three decades and includes thousands of studies in all therapeutic areas. The company serves more than 400 pharmaceutical, biotechnology, and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia. For more information, please visit www.bioclinica.com.
SOURCE BioClinica, Inc.